Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Real Time Quote from BATS)

$111.53 USD

111.53
394,122

+2.07 (1.89%)

Updated Apr 29, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalent (CTLT) Misses Q2 Earnings Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of -6.94% and 2.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?

by Zacks Equity Research

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival

by Zacks Equity Research

Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.

Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout

by Zacks Equity Research

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.

Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

by Zacks Equity Research

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug

by Zacks Equity Research

Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are Options Traders Betting on a Big Move in Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option

by Zacks Equity Research

Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

Implied Volatility Surging for Jazz Pharmaceuticals (JAZZ) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.

Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.

Why Jazz Pharmaceuticals (JAZZ) Might Surprise This Earnings Season

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

by Zacks Equity Research

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.

Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?

by Zacks Equity Research

The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.

Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.

Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.